News

Key Cancer Drugs to Watch at ESMO 2025: Investor and BD Insights

FDA · cancer · 5 min

European Navenibart Deal: A Strategic Win for BioCryst's Rare Disease Portfolio

FDA · rare disease · 4 min

EMA Horizon Scanning: Navigating Regulatory Updates for Future Medicines

FDA · 5 min

X4 Pharmaceuticals Secures Positive EMA CHMP Opinion for Mavorixafor in WHIM Syndrome

FDA · WHIM Syndrome · 5 min

Privosegtor Secures EMA PRIME Designation for Optic Neuritis Treatment

FDA · optic neuritis · 5 min

Arrowhead Pharmaceuticals Presents Positive Cardiometabolic Data at European A Meeting

FDA · Cardiometabolic disorders · 6 min

Teva's Olan EMA Application Acceptance: Strategic Implications for Pharma

FDA · 6 min

Florian Lordick Elected 2026 ESMO President: Implications for Global Oncology

FDA · oncology · 6 min

EMA Approves Novo's Wegovy: A Game Changer in Weight Loss

FDA · 6 min

DEFINITIVE Trial Milestone: 50% Recruitment Achieved

FDA · oncology · 7 min

EU Critical Medicines Act and China Supply Risk

7 min

EMA Approves New Medicines in January: Key Updates for Pharma Investors and BD Teams

EMA · 7 min